Clinical Trials Logo
  1. Home
  2. Peritoneal Carcinoma
  3. NCT04415944

Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy — HIPEC  

Peritoneal Carcinoma Clinical Trial

Official title:
A Phase II Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With HIPEC in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

Clinical Trial Summary

The purpose of this research study is to see if it is feasible to receive heated chemotherapy or heated intraperitoneal chemotherapy (HIPEC) inserted directly into the abdomen at the time of a Second Look Reassessment Surgery and to monitor any effects good or bad that this has on participants' health.

Clinical Trial Description

Primary Objective: Determine the feasibility of second look laparoscopy and hyperthermic intraperitoneal chemotherapy with carboplatin. Secondary Objective(s) - To compare the quality if life in patients with ovarian cancer after undergoing second look laparoscopic reassessment surgery with hyperthermic intraperitoneal chemotherapy using carboplatin (CBDCA) versus quality of life in patients treated with cytoreduction surgery and systemic chemotherapy alone. - To describe toxicities in patients with ovarian cancer treated with second look laparoscopy and simultaneous hyperthermic intraperitoneal chemotherapy. OUTLINE: Patients undergo second look laparoscopy. Patients with visible signs of cancer in abdomen also receive HIPEC with carboplatin via intraperitoneal injection (IP) over 90 minutes in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed for up to 6 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04415944
Study type Interventional
Source Wake Forest University Health Sciences
Contact Study Nurse
Phone 336-713-3539
Email arcarrol@wakehealth.edu
Status Recruiting
Phase Phase 2
Start date May 20, 2021
Completion date December 2024
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01936974 - (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma Phase 2
Completed NCT03480750 - Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer Phase 1/Phase 2
Completed NCT00181688 - Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer Phase 2
Terminated NCT00047632 - Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer Phase 3
Recruiting NCT03296826 - Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2
Active, not recruiting NCT03732781 - Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC Phase 1/Phase 2
Recruiting NCT06299163 - NM32-2668 in Adult Patients With Selected Advanced Solid Tumors Phase 1
Recruiting NCT04001023 - Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia N/A
Terminated NCT04158349 - Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer Phase 1
Not yet recruiting NCT06393543 - International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis
Not yet recruiting NCT06435689 - Study and Modulation of Immune Responses in Primary and Metastatic Colon Cancers
Completed NCT03056833 - Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer Phase 1
Terminated NCT01144442 - WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer N/A
Completed NCT02199171 - Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer Phase 1
Recruiting NCT04022213 - A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum Phase 2
Active, not recruiting NCT02125513 - Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer Phase 2
Terminated NCT01035658 - Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma Phase 1/Phase 2
Recruiting NCT05605535 - Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Phase 2
Recruiting NCT06290193 - Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery Phase 2
Completed NCT03931304 - Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Ovarian Cancer (Cyto-chip 2)